Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308231832> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W4308231832 abstract "Abstract Donor lymphocyte infusion using IL-2 activated donor lymphocytes following allogeneic stem cell transplantation (SCT) can sometimes eliminate multi-drug resistant (MDR) cancer cells and result in a cure. We hypothesized that more effective and faster immunotherapy could be accomplished by non-engrafting Intentionally Mismatched IL-2 Activated Killer cells (IMAK) with no prior SCT, avoiding the risks of GVHD due to consistent spontaneous rejection of killer cells after induction of cancer cytotoxicity. IMAK was applied for the compassionate treatment of 33 patients with MDR hematological malignancies following mild immunosuppressive conditioning. IMAK infusion was followed by low-dose subcutaneous IL-2 injections for ≤ 5 days for in vivo activation of donors’ and patients’ lymphocytes. Cumulative experience confirmed major anti-cancer responses following treatment with IMAK including in patients relapsing after myeloablative SCT. Treatment of relatively low tumor burden resulted in cure (> 5 to > 28 years unmaintained disease-free survival). Treatment was reasonably well-tolerated or manageable with no grade IV toxicity. Circulating donor lymphocytes were undetected beyond day + 6, confirming that early spontaneous rejection prevented the risk of GVHD-like toxicity. Immunotherapy potentially resulting in cure could be accomplished in patients with resistant hematologic malignancies when treated with relatively low tumor burden by transient circulation of IMAK. Since MRD can be accomplished in most patients with hematologic malignancies following successful first-line or high-dose chemotherapy, eradication of MRD in otherwise incurable patients could possibly be accomplished by IMAK. Prospective randomized clinical trials are indicated to confirm our working hypothesis." @default.
- W4308231832 created "2022-11-09" @default.
- W4308231832 creator A5059915616 @default.
- W4308231832 date "2022-11-03" @default.
- W4308231832 modified "2023-09-30" @default.
- W4308231832 title "Immunotherapy of multi-drug resistant hematologic malignancies with IL-2-activated intentionally mismatched lymphocytes" @default.
- W4308231832 cites W1545991364 @default.
- W4308231832 cites W1631222176 @default.
- W4308231832 cites W1707184873 @default.
- W4308231832 cites W1873141201 @default.
- W4308231832 cites W1985266211 @default.
- W4308231832 cites W2001499325 @default.
- W4308231832 cites W2022759117 @default.
- W4308231832 cites W2037692246 @default.
- W4308231832 cites W2066637360 @default.
- W4308231832 cites W2076636340 @default.
- W4308231832 cites W216764306 @default.
- W4308231832 cites W2297816245 @default.
- W4308231832 cites W2587940974 @default.
- W4308231832 doi "https://doi.org/10.21203/rs.3.rs-2220581/v1" @default.
- W4308231832 hasPublicationYear "2022" @default.
- W4308231832 type Work @default.
- W4308231832 citedByCount "0" @default.
- W4308231832 crossrefType "posted-content" @default.
- W4308231832 hasAuthorship W4308231832A5059915616 @default.
- W4308231832 hasBestOaLocation W43082318321 @default.
- W4308231832 hasConcept C121608353 @default.
- W4308231832 hasConcept C126322002 @default.
- W4308231832 hasConcept C143998085 @default.
- W4308231832 hasConcept C203014093 @default.
- W4308231832 hasConcept C2776694085 @default.
- W4308231832 hasConcept C2777408962 @default.
- W4308231832 hasConcept C2777701055 @default.
- W4308231832 hasConcept C2779695342 @default.
- W4308231832 hasConcept C2911091166 @default.
- W4308231832 hasConcept C29730261 @default.
- W4308231832 hasConcept C535046627 @default.
- W4308231832 hasConcept C71924100 @default.
- W4308231832 hasConceptScore W4308231832C121608353 @default.
- W4308231832 hasConceptScore W4308231832C126322002 @default.
- W4308231832 hasConceptScore W4308231832C143998085 @default.
- W4308231832 hasConceptScore W4308231832C203014093 @default.
- W4308231832 hasConceptScore W4308231832C2776694085 @default.
- W4308231832 hasConceptScore W4308231832C2777408962 @default.
- W4308231832 hasConceptScore W4308231832C2777701055 @default.
- W4308231832 hasConceptScore W4308231832C2779695342 @default.
- W4308231832 hasConceptScore W4308231832C2911091166 @default.
- W4308231832 hasConceptScore W4308231832C29730261 @default.
- W4308231832 hasConceptScore W4308231832C535046627 @default.
- W4308231832 hasConceptScore W4308231832C71924100 @default.
- W4308231832 hasLocation W43082318321 @default.
- W4308231832 hasOpenAccess W4308231832 @default.
- W4308231832 hasPrimaryLocation W43082318321 @default.
- W4308231832 hasRelatedWork W1961611968 @default.
- W4308231832 hasRelatedWork W2419299658 @default.
- W4308231832 hasRelatedWork W2552554696 @default.
- W4308231832 hasRelatedWork W2948610106 @default.
- W4308231832 hasRelatedWork W2994922817 @default.
- W4308231832 hasRelatedWork W3042191907 @default.
- W4308231832 hasRelatedWork W3137670083 @default.
- W4308231832 hasRelatedWork W4206639819 @default.
- W4308231832 hasRelatedWork W4290617554 @default.
- W4308231832 hasRelatedWork W4322718939 @default.
- W4308231832 isParatext "false" @default.
- W4308231832 isRetracted "false" @default.
- W4308231832 workType "article" @default.